An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512650-21-00

Acronym

IMVT-1401-3203

Enrollment

Registered

2024-07-15

Start date

2023-12-13

Completion date

Unknown

Last updated

2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Eye Disease (TED)

Brief summary

Duration of proptosis response off treatment in study eye in participants who were batoclimab responders in the feeder studies.

Detailed description

Proportion of proptosis responders at Week 24 in study eye in participants who were placebo non-responders in the feeder studies., Proportion of proptosis responders at Week 24 in study eye in participants who were batoclimab non-responders in the feeder studies.

Interventions

DRUGBatoclimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Duration of proptosis response off treatment in study eye in participants who were batoclimab responders in the feeder studies.	—

Secondary

Measure	Time frame
Proportion of proptosis responders at Week 24 in study eye in participants who were placebo non-responders in the feeder studies., Proportion of proptosis responders at Week 24 in study eye in participants who were batoclimab non-responders in the feeder studies.	—

Countries

Belgium, Hungary, Italy, Latvia, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026